Acuitas Therapeutics news
In recognition of his commitment to innovation and entrepreneurial spirit, Dr. Thomas Madden, President & CEO of Acuitas Therapeutics, has been named as one of seven Pacific winners in the EY Entrepreneur of the Year Award Program. He and the other Pacific award winners will go on to compete for 10 national titles and the overall top spot in Canada at the EY virtual celebration in November 2022. You can learn more about Dr. Madden and the other Pacific award winners here: https://go.ey.co
Michael Artley has joined Acuitas Therapeutics as Senior Director of Information Technology (IT), Abi Coman-Walker, Acuitas’ Chief Operating Officer, announced recently.
Mr. Artley will lead the company’s commitment in ensuring that information, systems, data and innovation continue to support Acuitas Therapeutics in its global mission of advancing human health. Prior to joining the Acuitas team, Mr. Artley was the Chief Information Officer for HSBC Bank Canada. He brings
Dr. Thomas Madden, President & CEO of Acuitas Therapeutics, is pleased to announce that Acuitas has been recognized as Company of the Year by Life Sciences BC (LSBC). Acuitas Therapeutics’ co-founder, Dr. Pieter Cullis, is this year’s recipient of LSBC’s Global Impact Award.
“We are honoured to have Acuitas Therapeutics named as Company of the Year by Life Sciences BC,” said Dr. Madden. “Vancouver’s life sciences sector is home to many except
The founders of Acuitas Therapeutics, Drs. Pieter Cullis, Michael Hope and Thomas Madden, have been named as Governor General’s Innovation Award recipients. This prestigious award is for their work in developing lipid nanoparticle (LNP) systems to deliver cancer drugs to tumours and to enable RNA- and DNA-based drugs to be used therapeutically. Among other achievements, their work has resulted in the LNP system that enables COMRINATY®, the Pfizer/BioNTech COVID-19 mRNA vaccine.
Abi Coman-Walker has been promoted to Chief Operating Officer (COO) at Acuitas Therapeutics, Dr. Thomas Madden, Acuitas President & CEO announced recently. Ms. Coman-Walker was the Senior Director of Finance & Operations at the private biotech firm.
Prior to joining Acuitas in early 2021, Ms. Coman-Walker worked at HSBC, where she held senior roles in seven countries including: Strategic Programme Director; Chief Operating Officer, Wealth and Personal Banking; and Global Head
Acuitas Therapeutics, a Vancouver-based, private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles, has donated $50,000 to the Canadian Red Cross to support that organization’s humanitarian efforts in Ukraine, President and CEO, Dr. Thomas Madden announced today.
Said Dr. Madden: “The unprovoked invasion of Ukraine by Russia has created a humanitarian crisis: supply chains are disrupted
- Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy
- Pfizer gains option to license Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development
Pfizer Inc. (NYSE: PFE) and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, to